MCID: RYN001
MIFTS: 49

Raynaud Disease

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Skin diseases

Aliases & Classifications for Raynaud Disease

MalaCards integrated aliases for Raynaud Disease:

Name: Raynaud Disease 57 12 44 15 17 70
Raynaud's Disease 12 42
Raynaud Syndrome 36 32
Secondary Raynaud's Phenomenon 70
Cold Fingers, Hereditary 57
Raynaud's Syndrome 12
Raynaud Phenomenon 70
Raynauds Syndrome 54

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant


HPO:

31
raynaud disease:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:10300
OMIM® 57 179600
KEGG 36 H01620
MeSH 44 D011928
SNOMED-CT 67 195295006
ICD10 32 I73.0
MedGen 41 C0034734
SNOMED-CT via HPO 68 263681008 266261006
UMLS 70 C0034734 C0034735 C1282916

Summaries for Raynaud Disease

MedlinePlus : 42 Raynaud's disease is a rare disorder of the blood vessels, usually in the fingers and toes. It causes the blood vessels to narrow when you are cold or feeling stressed. When this happens, blood can't get to the surface of the skin and the affected areas turn white and blue. When the blood flow returns, the skin turns red and throbs or tingles. In severe cases, loss of blood flow can cause sores or tissue death. Primary Raynaud's happens on its own. The cause is unknown. There is also secondary Raynaud's, which is caused by injuries, other diseases, or certain medicines. People in colder climates are more likely to develop Raynaud's. It is also more common in women, people with a family history, and those over age 30. Treatment for Raynaud's may include drugs to keep the blood vessels open. There are also simple things you can do yourself, such as Soaking hands in warm water at the first sign of an attack Keeping your hands and feet warm in cold weather Avoiding triggers, such as certain medicines and stress NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Raynaud Disease, also known as raynaud's disease, is related to raynaud phenomenon and scleroderma, familial progressive, and has symptoms including nausea and vomiting, constipation and fatigue. An important gene associated with Raynaud Disease is CENPB (Centromere Protein B), and among its related pathways/superpathways are Oxytocin signaling pathway and cGMP-PKG signaling pathway. The drugs Cilostazol and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include heart, smooth muscle and kidney, and related phenotypes are abnormality of the skeletal system and raynaud phenomenon

KEGG : 36 Raynaud syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. Although the underlying pathophysiological mechanism is unclear, alterations in activity of the peripheral adrenoceptor have been implicated, specifically an enhanced smooth muscle contraction due to overexpression or hyperactivity of postsynaptic alpha 2 receptors. RS can occur as an isolated entity, historically referred to as Raynaud disease or now primary RS, or in association with other conditions, most frequently the connective tissue diseases (eg, scleroderma [DS:H01492], systemic lupus erythematosus [DS:H00080], rheumatoid arthritis [DS:H00630], and Sjogren's syndrome [DS:H01502]), often referred to as Raynaud phenomenon or secondary RS. The diagnosis is mainly clinical, based on patient descriptions of skin changes. Therapy has been focused on the use of general vasodilation strategies.

Wikipedia : 73 Raynaud syndrome, also known as Raynaud's phenomenon, eponymously named after the physician, Auguste... more...

More information from OMIM: 179600

Related Diseases for Raynaud Disease

Diseases related to Raynaud Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 raynaud phenomenon 32.3 EDN1 CENPB ADRA2C
2 scleroderma, familial progressive 31.0 TOP1 EDN1 CENPB
3 angina pectoris 30.4 EDN1 CRP ACE
4 collagen disease 30.2 TRIM21 SNRNP70 CRP
5 buerger disease 30.1 EDN1 CRP
6 systemic scleroderma 30.1 TRIM21 TOP1 SNRNP70 EXOSC10 EDN1 CRP
7 fibromuscular dysplasia 30.1 AGTR1 ACE
8 constrictive pericarditis 30.0 CRP ACE
9 coronary artery vasospasm 30.0 EDN1 CRP ACE
10 peripheral artery disease 30.0 EDN1 CRP ACE
11 complex regional pain syndrome 29.9 EDN1 CALCA ACE
12 pulmonary edema 29.8 EDN1 CRP AGTR1 ACE
13 arteriosclerosis 29.8 EDNRA EDN1 CRP ACE
14 telangiectasis 29.8 TRIM21 TOP1 SNRNP70 EXOSC10 CENPB CENPA
15 parotitis 29.5 TRIM21 SSB CRP
16 diffuse scleroderma 29.4 TRIM21 TOP1 SNRNP70 EXOSC10 EDN1 CENPB
17 migraine with aura 29.2 EDNRB EDNRA EDN1 CALCA ACE
18 pulmonary hypertension 29.2 PDE5A EDNRB EDNRA EDN1 CRP AGTR1
19 crest syndrome 28.9 TOP1 SNRNP70 EXOSC10 EDNRB CENPB CENPA
20 migraine with or without aura 1 28.7 PDE5A EDNRB EDNRA EDN1 CRP CALCA
21 hypertension, essential 28.4 PDE5A EDNRB EDNRA EDN1 CRP CALCA
22 connective tissue disease 27.7 TOP1 SSB SNRNP70 EDNRB EDNRA EDN1
23 reynolds syndrome 11.3
24 retinal vasculopathy with cerebral leukodystrophy with systemic manifestations 11.0
25 cerebral arteritis 10.4 EDN1 CRP
26 conjunctival vascular disease 10.3 TRIM21 TOP1
27 chronic thromboembolic pulmonary hypertension 10.3 EDN1 CRP
28 granulomatous myositis 10.3 TRIM21 ACE
29 acute dacryoadenitis 10.3 CRP ACE
30 mediastinum teratoma 10.3 CRP ACE
31 cardiac tuberculosis 10.3 CRP ACE
32 kidney papillary necrosis 10.3 EDN1 ACE
33 posterior urethral valves 10.3 AGTR1 ACE
34 anterior scleritis 10.3 CRP ACE
35 multiple cranial nerve palsy 10.3 CRP ACE
36 cranial nerve palsy 10.3 CRP ACE
37 posterior scleritis 10.3 CRP ACE
38 tolosa-hunt syndrome 10.3 CRP ACE
39 chronic orbital inflammation 10.3 CRP ACE
40 idiopathic edema 10.3 EDN1 ACE
41 silent myocardial infarction 10.3 CRP ACE
42 glossopharyngeal nerve disease 10.3 CRP ACE
43 granulomatous angiitis 10.3 CRP ACE
44 urinary tract infection 10.3 CRP ACE
45 vasculogenic impotence 10.3 PDE5A ACE
46 neuroretinitis 10.3 CRP ACE
47 cholesterol embolism 10.3 CRP ACE
48 bladder neck obstruction 10.3 PDE5A ACE
49 optic papillitis 10.3 CRP ACE
50 granulomatous hepatitis 10.3 CRP ACE

Graphical network of the top 20 diseases related to Raynaud Disease:



Diseases related to Raynaud Disease

Symptoms & Phenotypes for Raynaud Disease

Human phenotypes related to Raynaud Disease:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 31 HP:0000924
2 raynaud phenomenon 31 HP:0030880

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Limbs:
intermittent attacks of numb and white fingers

Clinical features from OMIM®:

179600 (Updated 20-May-2021)

UMLS symptoms related to Raynaud Disease:


nausea and vomiting; constipation; fatigue; fever; angina pectoris; abdominal pain; chest pain; headache; pruritus; syncope; diarrhea; edema; pain; chronic pain; sciatica; halitosis; dyspepsia; icterus; coughing; vertigo/dizziness; symptoms; heartburn; gastrointestinal gas; pelvic pain; cold intolerance; joint or joint related complaint

Drugs & Therapeutics for Raynaud Disease

Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
3 Fibrinolytic Agents Phase 4
4 Respiratory System Agents Phase 4
5 Anti-Asthmatic Agents Phase 4
6 Phosphodiesterase 3 Inhibitors Phase 4
7 Bronchodilator Agents Phase 4
8 Neurotransmitter Agents Phase 4
9 abobotulinumtoxinA Phase 4
10 Cholinergic Agents Phase 4
11 Botulinum Toxins, Type A Phase 4
12 Botulinum Toxins Phase 4
13 Pharmaceutical Solutions Phase 4
14
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
15
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
16
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
17
Nitroglycerin Approved, Investigational Phase 2, Phase 3 55-63-0 4510
18
Prilocaine Approved Phase 3 721-50-6 4906
19
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
20
Nitrous oxide Approved, Vet_approved Phase 3 10024-97-2 948
21
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
22
Nifedipine Approved Phase 3 21829-25-4 4485
23
Bupivacaine Approved, Investigational Phase 2, Phase 3 38396-39-3, 2180-92-9 2474
24
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
26
Fasudil Investigational Phase 3 103745-39-7
27 Vasodilator Agents Phase 3
28 Phosphodiesterase Inhibitors Phase 3
29 Phosphodiesterase 5 Inhibitors Phase 3
30 Calcium, Dietary Phase 3
31 calcium channel blockers Phase 3
32 Vardenafil Dihydrochloride Phase 2, Phase 3
33 insulin Phase 3
34 Insulin, Globin Zinc Phase 3
35 Citrate Phase 2, Phase 3
36 Tocolytic Agents Phase 3
37 Sildenafil Citrate Phase 3 171599-83-0
38 Protein Kinase Inhibitors Phase 3
39 Anticoagulants Phase 3
40 Chelating Agents Phase 3
41 Platelet Aggregation Inhibitors Phase 3
42 Anesthetics Phase 2, Phase 3
43 Anesthetics, Local Phase 2, Phase 3
44
Calcium Nutraceutical Phase 3 7440-70-2 271
45
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46
Alprostadil Approved, Investigational Phase 2 745-65-3 149351 5280723
47
Riociguat Approved Phase 2 625115-55-1
48
Selexipag Approved Phase 2 475086-01-2
49 Antihypertensive Agents Phase 2
50 Ginkgo Phase 2

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed NCT00048776 Phase 4 Pletal
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed NCT00048763 Phase 4 Pletal
3 The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial Terminated NCT03639766 Phase 4 AbobotulinumtoxinA
4 A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
5 A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
6 Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
7 Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
8 A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
9 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
10 Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
11 Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
12 Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
13 A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
14 Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study to Assess Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis Completed NCT03717961 Phase 3 BOTOX® solution;Placebo group
15 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study Completed NCT01117298 Phase 3 Tadalafil;Placebo
16 Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP) Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
17 Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
18 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
19 Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
20 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
21 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study) Active, not recruiting NCT04040322 Phase 3 Placebo IV infusion;Iloprost Injection, for intravenous use
22 Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
23 Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
24 A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits Completed NCT01309802 Phase 2 onabotulinum toxin type-A
25 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT03867097 Phase 2 Placebo IV infusion;Iloprost Injection, for intravenous use
26 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis Completed NCT00707187 Phase 2 Cialis
27 A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
28 Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP) Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
29 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
30 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
31 A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc) Completed NCT04388176 Phase 2 C21;C21;Placebo;Placebo
32 A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
33 A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma) Completed NCT02228850 Phase 2 Alprostadil
34 A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
35 A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease. Completed NCT00528242 Phase 2 SLx-2101;Placebo
36 Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
37 A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc) Recruiting NCT04744207 Phase 2 GS-248;Placebo
38 Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
39 MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP
40 A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
41 Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy Unknown status NCT01378845 Tracleer;Prostavasin
42 Rôle Des Acides Epoxy-eicosatriénoïques et du Monoxyde d'Azote Dans l'hyperhémie Post-occlusive cutanée Digitale et la réponse cutanée au Froid Dans le phénomène de Raynaud Primaire Unknown status NCT02183779 L-NMMA and Fluconazole dermic injection
43 Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon Completed NCT02683408
44 RaynAUT - Thermography and the Autonomic Nervous System in Raynaud's Phenomenon - Investigation of the Autonomic Nervous System in Patients With Raynaud's Phenomenon, Glaucoma, and Autonomic Neuropathy. Completed NCT03094910
45 Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. Completed NCT03211325
46 Tadalafil for the Treatment of Secondary Raynaud's Phenomenon Completed NCT00822354 Tadalafil
47 Botulinum Toxin in the Treatment of Raynaud's Completed NCT01233999 botulinum toxin A
48 A Randomized, Single-blinded Placebo-controlled Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP) Completed NCT02506062
49 Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon Completed NCT02202291
50 Effectiveness of an Intervention Program With Electric Stimulation Therapy in Patients With Raynaud's Phenomenon: a Randomized Clinical Trial Completed NCT03699436

Search NIH Clinical Center for Raynaud Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Captopril
Isoxsuprine
Isoxsuprine Hydrochloride
Papaverine
Papaverine Hydrochloride
Prazosin
Prazosin hydrochloride
Tolazoline
Tolazoline Hydrochloride

Cochrane evidence based reviews: raynaud disease

Genetic Tests for Raynaud Disease

Anatomical Context for Raynaud Disease

MalaCards organs/tissues related to Raynaud Disease:

40
Heart, Smooth Muscle, Kidney, Skin, Spinal Cord, Endothelial, Lung

Publications for Raynaud Disease

Articles related to Raynaud Disease:

(show top 50) (show all 1028)
# Title Authors PMID Year
1
Familial aggregation of primary Raynaud's disease. 61 57
8670329 1996
2
Nailfold capillaroscopy in Sjögren's syndrome: a systematic literature review and standardised interpretation. 42
33025880 2020
3
Consensus-based evaluation of dermatoscopy versus nailfold videocapillaroscopy in Raynaud's phenomenon linking USA and Europe: a European League against Rheumatism study group on microcirculation in rheumatic diseases project. 42
32865167 2020
4
Incidence, Characteristics, Laboratory Findings and Outcomes in Acro-Ischemia in COVID-19 Patients. 42
33262599 2020
5
Renin-angiotensin system mediators and Raynaud's phenomenon. 61 54
17003081 2006
6
Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. 61 54
10334963 1999
7
Cutaneous responses to endothelin-1 and histamine in patients with vibration white finger. 54 61
9457906 1998
8
Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's disease. 54 61
9595516 1998
9
Highlights on endothelins: a review. 61 54
9441724 1997
10
Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. 61 54
8129780 1994
11
[New therapeutic possibilities with drugs affecting serotonin receptors]. 54 61
1509427 1992
12
Raynaud's phenomenon and related vasospastic disorders. 61
33566754 2021
13
Predicting Negative Outcomes of Cryolipolysis in Patients With and Without Raynaud Disease. 61
33625134 2021
14
Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience. 61
33549135 2021
15
Sudden onset peripheral visual deficit secondary to retinal artery spasm in Raynaud's phenomenon. 61
33547102 2021
16
Cyanosis With Dysautonomia Mimics Raynaud Disease. 61
31389817 2020
17
Alexithymia and emotion regulation in patients with Raynaud's disease. 61
32149407 2020
18
Arterial palmar arch occlusion in a woman with Raynaud's disease taking oral combined menopausal hormone therapy: A case report. 61
32373479 2020
19
The Use of Ultrasound Guidance for the Treatment of Raynaud Disease of the Hand With Botulinum Toxin. 61
32356950 2020
20
Right Ventricular Perforation Presenting as Tingling of the Left Breast. 61
32467814 2020
21
Rhabdomyolysis as an initial presentation of systemic lupus erythematosus: a case report. 61
31703554 2019
22
Computed Tomography (CT)-Guided Percutaneous Thoracic Sympathetic Chain Radiofrequency Thermocoagulation for Raynaud Disease. 61
31576813 2019
23
[Antisynthetase syndromes]. 61
31346706 2019
24
Immunologic adverse reactions of β-blockers and the skin. 61
31384329 2019
25
Primary Raynaud Disease. 61
31135869 2019
26
Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy. 61
30260839 2019
27
An Atypical Presentation of Raynaud's Disease. 61
30856621 2019
28
Acupuncture Point "Hegu" (LI4) Is Close to the Vascular Branch from the Superficial Branch of the Radial Nerve. 61
31341499 2019
29
Systemic Sclerosis and Serum Content of Transforming Growth Factor. 61
30758773 2019
30
A Literature Based Discovery Visualization System with Hierarchical Clustering and Linking Set Associations. 61
31259013 2019
31
The importance of perfusion index monitoring in evaluating the efficacy of stellate ganglion blockage treatment in Raynaud's disease. 61
29350104 2018
32
New onset acute pulmonary edema after methylergonovine given during cesarean delivery of a patient with undiagnosed Raynaud's disease. 61
30392649 2018
33
Anatomical Variation of the Radial Artery Associated With Clinically Significant Ischemia. 61
29602651 2018
34
Vascular branches from cutaneous nerve of the forearm and hand: Application to better understanding raynaud's disease. 61
28960445 2018
35
Effects of Endoscopic Thoracic Sympathectomy on Raynaud's Disease. 61
29327980 2018
36
[Quality of life of patients with Raynaud's disease]. 61
29658285 2018
37
Agreement between ccNexfin CO-trek cardiac output and intermittent cold-bolus pulmonary thermodilution in a prospective multicenter study. 61
29239149 2018
38
[Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients]. 61
29425538 2018
39
Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. 61
29044769 2018
40
Hyperbaric oxygen therapy for digital ulcers due to Raynaud's disease. 61
30397635 2018
41
Calcinosis Cutis: WOC Nurse Management. 61
29300294 2018
42
Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement. 61
28920529 2017
43
Classification of Japanese patients with mild/early systemic sclerosis (SSc) by the 2013 ACR/EULAR classification criteria for SSc. 61
27830961 2017
44
Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. 61
27682649 2017
45
[Hematopoietic stem cells transplant in patients with common variable immunodeficiency. Is a therapeutic option?] 61
28188718 2017
46
Acute Vision Loss Following Endoscopic Sinus Surgery. 61
28286685 2017
47
Thoracic sympathectomy for upper extremity ischemia. 61
27175977 2016
48
Comparison of Transradial vs Transfemoral Access for Aortoiliac and Femoropopliteal Interventions: A Single-Center Experience. 61
27558461 2016
49
Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. 61
27465880 2016
50
Endoscopic thoracic sympathectomy for upper limb ischemia. A 16 year follow-up in a single center. 61
25900032 2016

Variations for Raynaud Disease

Expression for Raynaud Disease

Search GEO for disease gene expression data for Raynaud Disease.

Pathways for Raynaud Disease

Pathways related to Raynaud Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.16 EDNRA EDN1 CALCA AGTR1
2
Show member pathways
12.16 PDE5A EDNRB EDNRA AGTR1 ADRA2C
3 11.22 EDNRB EDNRA EDN1
4 11.1 EDNRA EDN1 AGTR1 ACE
5 10.81 EDNRB EDNRA EDN1
6 10.46 EDNRB EDNRA EDN1 CALCA
7 10.27 EDNRA EDN1

GO Terms for Raynaud Disease

Biological processes related to Raynaud Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 9.72 EDNRB EDNRA EDN1 CALCA AGTR1
2 calcium-mediated signaling GO:0019722 9.71 EDNRB EDN1 AGTR1
3 regulation of pH GO:0006885 9.58 EDNRB EDN1
4 response to pain GO:0048265 9.58 EDNRB CALCA
5 regulation of sensory perception of pain GO:0051930 9.58 EDNRB EDN1 ADRA2C
6 enteric nervous system development GO:0048484 9.57 EDNRB EDNRA
7 positive regulation of renal sodium excretion GO:0035815 9.56 EDNRB EDN1
8 positive regulation of urine volume GO:0035810 9.55 EDNRB EDN1
9 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.54 EDN1 CALCA AGTR1
10 artery smooth muscle contraction GO:0014824 9.52 EDNRA EDN1
11 regulation of glucose transmembrane transport GO:0010827 9.51 EDNRA EDN1
12 epithelial fluid transport GO:0042045 9.49 EDNRB EDN1
13 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.48 AGTR1 ACE
14 negative regulation of cellular protein metabolic process GO:0032269 9.46 EDNRB EDN1
15 regulation of vasoconstriction GO:0019229 9.46 EDN1 AGTR1 ADRA2C ACE
16 vein smooth muscle contraction GO:0014826 9.43 EDNRB EDN1
17 endothelin receptor signaling pathway GO:0086100 9.43 EDNRB EDNRA EDN1
18 regulation of blood pressure GO:0008217 9.35 EDNRB EDNRA EDN1 CALCA ACE
19 vasoconstriction GO:0042310 8.92 EDNRB EDNRA EDN1 CRP

Molecular functions related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.46 RCC1 CENPA AGTR1 ADRA2C
2 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
3 endothelin receptor activity GO:0004962 8.62 EDNRB EDNRA

Sources for Raynaud Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....